Preventing respiratory complications

Peter Odor, Consultant in Anaesthesia and Perioperative Medicine, University College London Hospital





Challenges limiting evidence interpretation

- Huge, discordant evidence base to digest
- Variable definitions
 - Only recent consensus on what constitutes a PPC
 - EPCO 2015
 - StEP¹2018
- Lack of comprehensive evidence synthesis
 - 2006 American College of Physicians SR and guidelines²
- No standardised approach to management

- 1. Abbott et al. Br J Anaesth. 2018;120(5):1066-1079
- 2. Lawrence et al. Ann Intern Med 2006; 144:596–608.





Synthesis of evidence in progress

	Intervention (n/N)	Control (n/N)					RR (95% CI)	р	I ² (%)
ERAS	17/227	50/232	•				0.35 (0.21-0.58)	< 0.0001	0
Prophylactic mucolytic	17/225	44/227 -	•				0.40 (0.23-0.67)	0.0006	0
Post-operative CPAP	23/214	40/187	•				0.49 (0.24-0.99)	0.05	48
Lung protective ventilation	225/808	283/801					0.52 (0.30-0.88)	0.01	78
Respiratory physiotherapy	57/657	122/649					0.55 (0.32-0.93)	0.02	60
Restrictive vs. liberal fluids	14/396	27/399 —	•				0.55 (0.23-1.32)	0.18	26
Epidural analgesia	175/1247	232/1247	-	•			0.77 (0.65-0.92)	0.003	0
Post-operative bi-level NIV	59/195	62/197		•			0.78 (0.32-1.90)	0.58	49
Post-operative HFNC	21/164	26/166		•	-		0.83 (0.46-1.51)	0.55	6
Goal directed fluid therapy	223/2010	258/1935					0.87 (0.77-0.98)	0.02	0
Smoking cessation therapy	5/282	6/289					0.90 (0.30-2.68)	0.85	0
Prophylactic inhaled beta agonist	49/200	54/205					0.93 (0.67-1.29)	0.65	0
Incentive spirometry	132/965	125/975					1.06 (0.85-1.34)	0.59	0
High intraoperative FiO2 (0.8)	61/701	55/715					1.12 (0.80-1.58)	0.51	0
		0.2	0.5	1.0	2.0 Favours control	5.0			

• 112 RCTs meta-analysis, TSA





Pre-op

Recognise the high risk patient



Perioperative Quality Improvement Programme

University College London Hospitals NHS Foundation Trust

Intra-op

Protect against deleterious effects of surgery and general anaesthesia

Perioperative Quality

Improvement Programme

Non-controversial

Modifications to intraoperative ventilation parameters are a **low cost strategy** to protect against PPCs in major/prolonged surgery patients

NNT = 14 (95% Cl: 8.3-33.8)



Epidural analgesia has low quality evidence of efficacy in preventing PPCs



Goal directed fluid therapy has moderate quality evidence of efficacy, but small effect size

Controversial/ low grade evidence

- What constitutes the optimal mode of "protective ventilation"?
- Are benefits applicable to low risk patients?
- How should ventilation be modified in specific patient groups e.g. pre-existing lung disease, morbid obesity, or OLV?



Post-op

Lung expansion modalities

Perioperative Quality

Improvement Programme

Non-controversial



Supervised prophylactic respiratory physiotherapy has low quality evidence of efficacy Controversial/ low grade evidence



post-op CPAP (PRISM trial results pending...)

Moderate quality evidence that **incentive spirometry alone does not reduce PPCs**



HFNC and BIPAP have no evidence of efficacy



Summary and recommendations

- 1. PPCs have a major effect on hospital utilisation, healthcare costs and patient mortality
- 2. Surgical patients may benefit from pre-operative risk stratification for PPCs, using data to individualise perioperative strategies for PPC protection
- 3. Pre-op, intra-op and post-operative strategies available with variable quality evidence of efficacy
- 4. Local, multidisciplinary approach to patient pathways and bundles of care may help reduce PPCs



